Abstract
The authors present their concerns surrounding data presented in studies from 2018 and 2020 regarding very low dose bevacizumab for the treatment of retinopathy of prematurity. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:542-544.].
© 2020 Harper, Beck, Chang, Young, Moshfeghi.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Bevacizumab / administration & dosage*
-
Female
-
Fluorescein Angiography
-
Fundus Oculi
-
Gestational Age
-
Humans
-
Infant, Newborn
-
Intravitreal Injections
-
Laser Coagulation / methods*
-
Male
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Retinopathy of Prematurity / diagnosis
-
Retinopathy of Prematurity / therapy*
Substances
-
Angiogenesis Inhibitors
-
Bevacizumab
-
Receptors, Vascular Endothelial Growth Factor